GLP-1 Receptor Agonists in Neurodegeneration: Neurovascular Unit in the Spotlight

Defects in brain energy metabolism and proteopathic stress are implicated in age-related degenerative neuronopathies, exemplified by Alzheimer’s disease (AD) and Parkinson’s disease (PD). As the currently available drug regimens largely aim to mitigate cognitive decline and/or motor symptoms, there...

Full description

Bibliographic Details
Published in:	Cells
Main Authors:	Giulia Monti, Diana Gomes Moreira, Mette Richner, Henricus Antonius Maria Mutsaers, Nelson Ferreira, Asad Jan
Format:	Article
Language:	English
Published:	MDPI AG 2022-06-01
Subjects:	glucagon-like peptide-1 (GLP-1) Alzheimer’s disease Parkinson’s disease neurodegeneration neurovascular unit
Online Access:	https://www.mdpi.com/2073-4409/11/13/2023

Similar Items

Incretin-Based Multi-Agonist Peptides Are Neuroprotective and Anti-Inflammatory in Cellular Models of Neurodegeneration
by: Katherine O. Kopp, et al.
Published: (2024-07-01)

Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice
by: Patrick J. Knerr, et al.
Published: (2022-09-01)

The Neuroprotective Effects of GLP-1 Analogues on Alzheimer's Disease – A Literature Review
by: Wiktoria Ulicka, et al.
Published: (2025-04-01)

Application of GLP-1 receptor agonists in postoperative combined therapy for obesity: a perspective of metabolic surgery
by: MENG Hua, SONG Yujia, WANG Siqi
Published: (2025-05-01)

GLP-1 and Its Role in Glycogen Production: A Narrative Review
by: Joseph Lotosky, et al.
Published: (2025-06-01)

Potential impact of GLP-1 receptor agonists on male fertility: a fable of caution
by: Stefan S. Du Plessis, et al.
Published: (2024-11-01)

Targeting the GLP-1/GLP-1R axis to treat osteoarthritis: A new opportunity?
by: C. Meurot, et al.
Published: (2022-01-01)

GLP-1 Receptor Agonists: A Promising Therapy for Modern Lifestyle Diseases with Unforeseen Challenges
by: Patrycja Kupnicka, et al.
Published: (2024-11-01)

GLP-1 receptor agonist as an effective treatment for breast cancer-related lymphedema: a case report
by: Fionnuala Crowley, et al.
Published: (2024-04-01)

Glucagon‐like peptide agonists: A prospective review
by: Zamara Mariam, et al.
Published: (2024-01-01)

The impact of glucagon-like peptide-1 (GLP-1) agonists in the treatment of eating disorders: a systematic review and meta-analysis
by: Hanieh Radkhah, et al.
Published: (2025-02-01)

Future Perspectives on GLP-1 Receptor Agonists and GLP-1/glucagon Receptor Co-agonists in the Treatment of NAFLD
by: Marta Seghieri, et al.
Published: (2018-11-01)

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and cardiometabolic protection: historical development and future challenges
by: Francisco Westermeier, et al.
Published: (2025-01-01)

From classical dualistic antagonism to hormone synergy: potential of overlapping action of glucagon, insulin and GLP-1 for the treatment of diabesity
by: Svjatoslavs Kistkins, et al.
Published: (2024-05-01)

GLP-1 and GLP-2 Orchestrate Intestine Integrity, Gut Microbiota, and Immune System Crosstalk
by: Nyan Abdalqadir, et al.
Published: (2022-10-01)

Multifaceted Roles of GLP-1 and Its Analogs: A Review on Molecular Mechanisms with a Cardiotherapeutic Perspective
by: Sudhir Pandey, et al.
Published: (2023-06-01)

Secretion of glucagon, GLP-1 and GIP may be affected by circadian rhythm in healthy males
by: Dorte B. Zilstorff, et al.
Published: (2024-03-01)

GLP-1 receptor agonists—another promising therapy for Alport syndrome?
by: Jan Boeckhaus, et al.
Published: (2025-03-01)

Effects of exercise on glucagon-like peptide-1 (GLP-1)
by: Shin-ya Ueda, et al.
Published: (2013-06-01)

Improving Reproductive Outcomes in PCOS: The Emerging Role of GLP-1 Receptor Agonists
by: Adrianna Tabeau, et al.
Published: (2025-03-01)

Incretins role in Latent autoimmune diabetes of adults pathogenesis, the possibility of therapy with combination of glucagon-like peptide-1 agonist (GLP-1) and insulin.
by: Iuliia V. Silko, et al.
Published: (2016-07-01)

Early Intervention and Lifelong Treatment with GLP1 Receptor Agonist Liraglutide in a Wolfram Syndrome Rat Model with an Emphasis on Visual Neurodegeneration, Sensorineural Hearing Loss and Diabetic Phenotype
by: Toomas Jagomäe, et al.
Published: (2021-11-01)

Design and discovery of a highly potent ultralong-acting GLP-1 and glucagon co-agonist for attenuating renal fibrosis
by: Qian Zhao, et al.
Published: (2024-03-01)

Long-term cancer risk in users of GLP-1 agonists in Denmark: a nationwide emulated trialResearch in context
by: Mads Gamborg, et al.
Published: (2025-08-01)

Enhancing endogenous levels of GLP1 dampens acute olanzapine induced perturbations in lipid and glucose metabolism
by: Kyle D. Medak, et al.
Published: (2023-03-01)

Decreased incidence of hidradenitis suppurativa and psoriasis in diabetic patients treated with GLP-1 receptor agonists: A retrospective cohort study
by: Lauren M. Ching, BS, et al.
Published: (2025-10-01)

GLP-1 receptor agonists as promising disease-modifying agents in WFS1 spectrum disorder
by: Eleonora Panfili, et al.
Published: (2023-06-01)

GLP-1 receptor agonists in IBD: exploring the crossroads of metabolism and inflammation
by: Giulia Migliorisi, et al.
Published: (2025-07-01)

Effects of GLP-1 Receptor Polymorphisms on Adolescent Obesity
by: Mahafarin Maralani, et al.
Published: (2023-07-01)

Self-assembled GLP-1/glucagon peptide nanofibrils prolong inhibition of food intake
by: Myriam M. Ouberai, et al.
Published: (2023-07-01)

Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists
by: Qiyuan Keith Liu
Published: (2024-07-01)

Genetic variation in the glucagon-like peptide-1 receptor protein encoding region is associated with higher heart rate variability, but not with neurodegeneration of the brain, retina, and peripheral nerves: The Maastricht study
by: Frank C. T. van der Heide, et al.
Published: (2025-10-01)

Attenuated Postprandial GLP-1 Response in Parkinson’s Disease
by: Richard A. Manfready, et al.
Published: (2021-07-01)

Effect of survodutide, a glucagon and GLP-1 receptor dual agonist, on weight loss: a meta-analysis of randomized controlled trials
by: Haijun Wan, et al.
Published: (2024-11-01)

The VIP/VPAC1R Pathway Regulates Energy and Glucose Homeostasis by Modulating GLP-1, Glucagon, Leptin and PYY Levels in Mice
by: Daniel Sanford, et al.
Published: (2022-03-01)

The GLP-1 receptor is expressed in vivo by human metastatic prostate cancer
by: Mark S Stein, et al.
Published: (2024-01-01)

Revolutionizing Diabetes and Obesity Management: A Comprehensive Review of Tirzepatide’s Dual Agonist Approach
by: Sonam Samal, et al.
Published: (2024-04-01)

Exploring the Role of GLP-1 Receptor Agonists in Alzheimer’s Disease: A Review of Preclinical and Clinical Evidence
by: Lívia C. R. Teixeira, et al.
Published: (2025-01-01)

Emerging Role of Caveolin-1 in GLP-1 Action
by: Alessandra Puddu, et al.
Published: (2021-04-01)

Variation in the Evolution and Sequences of Proglucagon and the Receptors for Proglucagon-Derived Peptides in Mammals
by: David M. Irwin, et al.
Published: (2021-07-01)